Recent epidemiologic evidence suggests that higher circulating 25-hydroxyvitamin D does not protect against prostate cancer and, in fact, may increase the risk of developing this malignancy. However, few studies have examined the most clinically relevant outcome, prostate cancer mortality.

This study showed in a population of men diagnosed with prostate cancer, higher serum 25(OH)D years prior to diagnosis was associated with longer prostate cancer survival.

Read the article.

Leave a Comment